Covid-19 roundup: South African variant trips up Pfizer/BioNTech, Moderna vaccines while EU seeks anti-variant contract clauses — report
As questions continue to swirl about the effectiveness of current vaccines against new variants of the coronavirus, a pair of letters to the editor confirm that those developed by Pfizer/BioNTech and Moderna appear to be able to protect against the UK variant but less efficacious when faced with the strain originating from South Africa.
Now that the first-generation vaccines’ efficacy against the original SARS-CoV-2 antigen has largely been established, some scientists have turned their attention to the questions of when, where and how they can be best deployed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
